Literature DB >> 25366111

Alzheimer disease: the landscape of ageing--insights from AD imaging markers.

Victor L Villemagne1, Colin L Masters2.   

Abstract

The knowledge of imaging and fluid biomarkers gained from longitudinal observational studies of Alzheimer disease has recently been translated to a cross-sectional study of randomly selected, cognitively unimpaired elderly individuals. This is the first time that a two-feature biomarker classification system has been applied to a population-based cohort.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25366111     DOI： 10.1038/nrneurol.2014.214

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  10 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

3.  An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.

Authors:  Clifford R Jack; David S Knopman; Stephen D Weigand; Heather J Wiste; Prashanthi Vemuri; Val Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Robert J Ivnik; Rosebud O Roberts; Walter A Rocca; Bradley F Boeve; Ronald C Petersen
Journal:  Ann Neurol       Date:  2012-04-09       Impact factor: 10.422

Review 4.  The Parkinson Progression Marker Initiative (PPMI).

Authors: 
Journal:  Prog Neurobiol       Date:  2011-09-14       Impact factor: 10.885

5.  Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.

Authors:  Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Andrew Ward; Willem Huijbers; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  Neurology       Date:  2014-04-18       Impact factor: 9.910

6.  Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen
Journal:  Lancet Neurol       Date:  2014-09-04       Impact factor: 44.182

7.  Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.

Authors:  Miranka Wirth; Sylvia Villeneuve; Claudia M Haase; Cindee M Madison; Hwamee Oh; Susan M Landau; Gil D Rabinovici; William J Jagust
Journal:  JAMA Neurol       Date:  2013-12       Impact factor: 18.302

8.  Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.

Authors:  Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  JAMA Neurol       Date:  2014-11       Impact factor: 18.302

Review 9.  Imago Mundi, Imago AD, Imago ADNI.

Authors:  Victor L Villemagne; Seong Yoon Kim; Christopher C Rowe; Takeshi Iwatsubo
Journal:  Alzheimers Res Ther       Date:  2014-08-29       Impact factor: 6.982

10.  APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.

Authors:  Y Y Lim; V L Villemagne; S M Laws; R H Pietrzak; P J Snyder; D Ames; K A Ellis; K Harrington; A Rembach; R N Martins; C C Rowe; C L Masters; P Maruff
Journal:  Mol Psychiatry       Date:  2014-10-07       Impact factor: 15.992
  10 in total
  6 in total

1.  Astragalin alleviates cognitive deficits and neuronal damage in SAMP8 mice through upregulating estrogen receptor expression.

Authors:  Hong Liu; Lili Zhong; Qiaomei Dai; Yuwei Zhang; Jing Yang
Journal:  Metab Brain Dis       Date:  2022-08-19       Impact factor: 3.655

Review 2.  Targeting Novel microRNAs in Developing Novel Alzheimer's Disease Treatments.

Authors:  Fatemehsadat Seyedaghamiri; Mojgan Rajabi; Gisou Mohaddes
Journal:  Neurochem Res       Date:  2022-09-01       Impact factor: 4.414

Review 3.  Roles of Gut Microbiota in Pathogenesis of Alzheimer's Disease and Therapeutic Effects of Chinese Medicine.

Authors:  Ying-Xin Sun; Xi-Juan Jiang; Bin Lu; Qing Gao; Ye-Fei Chen; Dan-Bin Wu; Wen-Yun Zeng; Lin Yang; Hu-Hu Li; Bin Yu
Journal:  Chin J Integr Med       Date:  2020-09-01       Impact factor: 2.626

Review 4.  Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease.

Authors:  Xian-Le Bu; Shu-Sheng Jiao; Yan Lian; Yan-Jiang Wang
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

5.  Abnormal gut microbiota composition contributes to cognitive dysfunction in SAMP8 mice.

Authors:  Gaofeng Zhan; Ning Yang; Shan Li; Niannian Huang; Xi Fang; Jie Zhang; Bin Zhu; Ling Yang; Chun Yang; Ailin Luo
Journal:  Aging (Albany NY)       Date:  2018-06-10       Impact factor: 5.682

6.  PIAS3 suppresses damage in an Alzheimer's disease cell model by inducing the STAT3-associated STAT3/Nestin/Nrf2/HO-1 pathway.

Authors:  Chen Li; Ruili Wang; Youyou Zhang; Chunting Hu; Qiaoya Ma
Journal:  Mol Med       Date:  2021-11-27       Impact factor: 6.354
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.